| Date | Title | Description |
| 28.08.2026 | Year-end Report (Q4) July 2025 – June 2026 | Year-end Report (Q4) July 2025 – June 2026
Fri, Aug 28, 2026 09:00 CET Report this content
Strong progress in Cancer Therapy and Novel treatments of bacterial infections
“We have reached major goals in the fields of Cancer Therapy and Novel... |
| 28.07.2026 | Grant and impending grant of new patents in the US and Japan | Grant and impending grant of new patents in the US and Japan
Tue, Jul 28, 2026 13:00 CET Report this content
Hamlet Biopharma, a company innovating the treatment of cancer and infections, today announced the grant and impending grant of new... |
| 24.07.2026 | International traction for Hamlet BioPharma | International traction for Hamlet BioPharma
Fri, Jul 24, 2026 09:00 CET Report this content
Time Business News and USA Wire both highlight Hamlet Biopharma's EMA approval for the phase III study of neoaduvant therapy for early bladder cance... |
| 29.06.2026 | Briefglance Highlights Hamlet BioPharma's Collaboration with the University of Iowa and the Potential for Advanced Bladder Cancer Therapy | Briefglance Highlights Hamlet BioPharma's Collaboration with the University of Iowa and the Potential for Advanced Bladder Cancer Therapy
Mon, Jun 29, 2026 10:35 CET Report this content
The digital analytics platform Briefglance has highlig... |
| 29.06.2026 | Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer | Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer
Mon, Jun 29, 2026 14:07 CET Report this content
Hamlet BioPharma, a pharmaceutical company specializing in the development of novel trea... |
| 25.06.2026 | Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites | Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites
Thu, Jun 25, 2026 16:00 CET Report this content
Hamlet BioPharma today announces the successful release of the ... |
| 23.06.2026 | Hamlet BioPharma’s monthly digital investors’ meeting on June 30th | Hamlet BioPharma’s monthly digital investors’ meeting on June 30th
Tue, Jun 23, 2026 12:00 CET Report this content
Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 30th of June 2026, at 12:00.
Please click on... |
| 22.06.2026 | Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC) | Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)
Mon, Jun 22, 2026 17:30 CET Report this content
Hamlet BioPharma AB (publ) today ann... |
| 17.06.2026 | Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer | Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer
Wed, Jun 17, 2026 11:45 CET Report this content
Hamlet BioPharma AB (publ) today conducted a pre-initiation visit at the Department of Urology at Charles U... |
| 10.06.2026 | Continued success for the new anti-infective therapies developed by Hamlet BioPharma | Continued success for the new anti-infective therapies developed by Hamlet BioPharma
Wed, Jun 10, 2026 14:30 CET Report this content
The Journal of Infectious Diseases publishes the paper “Targeting the disease response with NlpD and LytM f... |
| 21.05.2026 | Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it’s Q3 report | Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it’s Q3 report
Thu, May 21, 2026 11:15 CET Report this content
Hamlet BioPharma invites you to the investors’ meeting to be held on the 22nd of May 2026, at 12:0... |
| 18.05.2026 | Hamlet Biopharma Secures New Patents and Allowances, Going from Strength to Strength in Innovation and Technology | Hamlet Biopharma Secures New Patents and Allowances, Going from Strength to Strength in Innovation and Technology
Mon, May 18, 2026 15:15 CET Report this content
Hamlet Biopharma, a company innovating the treatment of cancer and infections,... |
| 23.04.2026 | Monthly investor meeting on the 29th of April | Monthly investor meeting on the 29th of April
Thu, Apr 23, 2026 15:15 CET Report this content
Hamlet BioPharma invites you to the monthly digital investors’ meeting to be held on the 29th of April 2026, at 12:00.
Please click on the link be... |
| 30.03.2026 | Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026 | Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026
Mon, Mar 30, 2026 10:00 CET Report this content
Hamlet BioPharma AB, an innovative pharmaceutical company developing new therapies for cancer and infections, anno... |
| 17.03.2026 | Hamlet BioPharmas digital monthly investor meeting on the 18th of March | Hamlet BioPharmas digital monthly investor meeting on the 18th of March
Tue, Mar 17, 2026 10:00 CET Report this content
Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 18th of March 2026, at 12:00.
Please cl... |
| 06.03.2026 | Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H. | Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H.
Fri, Mar 06, 2026 18:31 CET Report this content
Hamlet BioPharma AB (Hamlet), a clinical‑stage biopharm... |
| 12.02.2026 | Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’ | Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’
Thu, Feb 12, 2026 17:03 CET Report this content
This groun... |
| 11.02.2026 | Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it’s Q2 report | Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it’s Q2 report
Wed, Feb 11, 2026 10:30 CET Report this content
Hamlet BioPharma invites you to our February investors’ meeting to be held on the 13th of Feb... |
| 03.02.2026 | Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea | Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea
Tue, Feb 03, 2026 10:15 CET Report this content
Hamlet BioPharma has signed an agreement with the Korean biotech company ImmunoForge, to develop novel administr... |
| 27.01.2026 | 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 | 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿
Tue, Jan 27, 2026 12:00 CET Report this content
We warmly welcome you to the Symposium on “𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿.” The invited speaker ...... |
| 16.01.2026 | Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics | Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics
Fri, Jan 16, 2026 14:00 CET Report this content
Welcome to Hamlet BioPharma’s monthly digital meeting on January 21 at 12:00, h... |
| 05.11.2025 | Clinical study in infants with febrile kidney infection supports Hamlet BioPharma’s strategy for non-antibiotic treatment of bacterial infections | Clinical study in infants with febrile kidney infection supports Hamlet BioPharma’s strategy for non-antibiotic treatment of bacterial infections
Wed, Nov 05, 2025 14:00 CET Report this content
One of the most comprehensive studies ever con... |
| 23.09.2025 | Monthly investor meeting on the 25th of September | Monthly investor meeting on the 25th of September
Tue, Sep 23, 2025 09:00 CET Report this content
Hamlet BioPharma invites you to our September investors’ meeting to be held on the 25th of September 2025, at 12:00.
Please click on the link ... |
| 22.09.2025 | Hamlet BioPharma prepares for next steps and secures drug manufacturing of Alpha1H at Phase III quality | Hamlet BioPharma prepares for next steps and secures drug manufacturing of Alpha1H at Phase III quality
Mon, Sep 22, 2025 13:53 CET Report this content
Hamlet BioPharma, ticker Hamlet, the pharmaceutical company specializing in the developm... |
| 21.08.2025 | Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer | Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer
Thu, Aug 21, 2025 11:15 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of d... |
| 18.07.2025 | Hamlet BioPharma proposes a directed new share issue to finance continued development and commercialization based on three positive Phase II studies | Hamlet BioPharma proposes a directed new share issue to finance continued development and commercialization based on three positive Phase II studies
Fri, Jul 18, 2025 14:58 CET Report this content
Lund, 18 July 2025, Hamlet BioPharma, an in... |
| 25.06.2025 | Hamlet BioPharma Holds Successful In Person Meeting with US FDA | Hamlet BioPharma Holds Successful In Person Meeting with US FDA
Wed, Jun 25, 2025 15:50 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, today announce... |
| 17.06.2025 | Hamlet BioPharma invites to investor meeting on the 18th of June | Hamlet BioPharma invites to investor meeting on the 18th of June
Tue, Jun 17, 2025 10:00 CET Report this content
As previously announced Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the18th of June 2025, at 1... |
| 17.06.2025 | Hamlet BioPharma announces progress in Tuberculosis therapy | Hamlet BioPharma announces progress in Tuberculosis therapy
Tue, Jun 17, 2025 14:06 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, today announces pr... |
| 22.05.2025 | Q3 INTERIM REPORT JANUARY – MARCH 2025 | Q3 INTERIM REPORT JANUARY – MARCH 2025
Thu, May 22, 2025 09:00 CET Report this content
OPENING REMARKS
Hamlet BioPharma’s drug candidate Alpha1H has shown effective tumor-killing capabilities against bladder cancer cells and demonstrated st... |
| 19.05.2025 | Scientific Breakthrough in Alpha1H’s Mechanism of Action | Scientific Breakthrough in Alpha1H’s Mechanism of Action
Mon, May 19, 2025 13:21 CET Report this content
As previously reported, Hamlet BioPharma has achieved a groundbreaking scientific discovery related to Alpha1H, the company’s lead drug... |
| 22.04.2025 | Hamlet BioPharma invites to investor meeting on the 23rd of April | Hamlet BioPharma invites to investor meeting on the 23rd of April
Tue, Apr 22, 2025 14:38 CET Report this content
As previously announced Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 23rd of April 2025, a... |
| 08.04.2025 | New discoveries in infection biology, highlighting the rich potential of non-antibiotic treatments of infections | New discoveries in infection biology, highlighting the rich potential of non-antibiotic treatments of infections
Tue, Apr 08, 2025 09:47 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development o... |
| 08.04.2025 | New scientific advances for Alpha1H highlight the unique discovery pipeline and drug development potential for the treatment of bladder cancer | New scientific advances for Alpha1H highlight the unique discovery pipeline and drug development potential for the treatment of bladder cancer
Tue, Apr 08, 2025 09:52 CET Report this content
Hamlet BioPharma, the pharmaceutical company, spe... |
| 07.04.2025 | Strong Alpha1H treatment effects confirmed in patients with bladder cancer, in final analysis. Clinical study report is being completed for submission to the FDA | Strong Alpha1H treatment effects confirmed in patients with bladder cancer, in final analysis. Clinical study report is being completed for submission to the FDA
Mon, Apr 07, 2025 16:32 CET Report this content
Hamlet BioPharma, the pharmace... |
| 07.04.2025 | New granted patents added to Hamlet BioPharma's extensive patent portfolio in cancer and infection | New granted patents added to Hamlet BioPharma's extensive patent portfolio in cancer and infection
Mon, Apr 07, 2025 16:57 CET Report this content
Hamlet BioPharma's extensive patent portfolio comprises 147 granted patents and 33 pending ca... |
| 28.11.2024 | Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024 | Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024
Thu, Nov 28, 2024 13:25 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and... |
| 19.11.2024 | Hamlet BioPharma Participates in the BioStock Life Science Summit 2024 | Hamlet BioPharma Participates in the BioStock Life Science Summit 2024
Tue, Nov 19, 2024 16:49 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announc... |
| 04.11.2024 | Two in-depth features about Hamlet BioPharma in the prestigious CEO world magazines and pulse 2.0 business news website | Two in-depth features about Hamlet BioPharma in the prestigious CEO world magazines and pulse 2.0 business news website
Mon, Nov 04, 2024 10:33 CET Report this content
Hamlet BioPharma, ticker HAMLET B, the innovative pharmaceutical company... |
| 13.09.2024 | New Frontiers in Bladder Cancer Treatment and Alzheimer’s Research: A Dual Perspective | In the realm of medical science, breakthroughs often come with the force of a tidal wave. Two recent studies highlight this dynamic, one focusing on bladder cancer and the other on Alzheimer’s disease. Each represents a significant leap for... |
| 13.09.2024 | The Healing Power of Human Milk: A New Frontier in Cancer Treatment | In a world where science often feels like a maze, a beacon of hope shines through the research on human breast milk. The recent feature in *The Economist* highlights groundbreaking work from Lund University, focusing on a compound known as ... |
| 12.09.2024 | The Economist features groundbreaking research on human breast milk and the story of HAMLET | The Economist features groundbreaking research on human breast milk and the story of HAMLET
Thu, Sep 12, 2024 10:55 CET Report this content
Hamlet BioPharma is pleased to announce a recent article about human breast milk in The Economist, a... |
| 11.09.2024 | Alpha1H treatment shows strong effects in patients with bladder cancer in final analysis published in Cancer Medicine | Alpha1H treatment shows strong effects in patients with bladder cancer in final analysis published in Cancer Medicine
Wed, Sep 11, 2024 13:26 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the developm... |
| 28.08.2024 | Year-end Report (Q4) July 2023 – June 2024 | Year-end Report (Q4) July 2023 – June 2024
Wed, Aug 28, 2024 09:49 CET Report this content
OPENING REMARKS
The fiscal year 2023-2024 has been very productive, eventful and successful for Hamlet Biopharma, addressing the need for new treatme... |
| 27.05.2024 | Hamlet BioPharma Participates in The Global Forum 2024 | Hamlet BioPharma Participates in The Global Forum 2024
Mon, May 27, 2024 13:30 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announce its participat... |
| 06.05.2024 | Clinical data from patients with bladder pain syndrome support anakinra (IL1-RA) as a new, successful treatment option | Clinical data from patients with bladder pain syndrome support anakinra (IL1-RA) as a new, successful treatment option
Mon, May 06, 2024 10:40 CET Report this content
Hamlet BioPharma - the pharmaceutical company with a strong portfolio of ... |
| 18.04.2024 | Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group | Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group
Thu, Apr 18, 2024 09:41 CET Report this content
Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the ... |
| 03.04.2024 | Immune responses in patients treated with Alpha1H - results published in the journal Cancer Medicine | Immune responses in patients treated with Alpha1H - results published in the journal Cancer Medicine
Wed, Apr 03, 2024 10:37 CET Report this content
Hamlet BioPharma announced on January 25 that clinical data showed a strong immune response... |
| 26.03.2024 | Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024 | Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024
Tue, Mar 26, 2024 10:28 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and... |
| 06.03.2024 | Hamlet BioPharma Participates in Swiss Nordic Bio 2024 | Hamlet BioPharma Participates in Swiss Nordic Bio 2024
Wed, Mar 06, 2024 09:39 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, is proud to announce it... |
| 14.02.2024 | Hamlet BioPharma Enters Commercial Collaborations with Top International Advisory Firms to Enhance Partnering and Strategic Alliances | Hamlet BioPharma Enters Commercial Collaborations with Top International Advisory Firms to Enhance Partnering and Strategic Alliances
Wed, Feb 14, 2024 11:21 CET Report this content
Hamlet BioPharma, the pharmaceutical company, specializing... |
| 25.01.2024 | New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effects | New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effects
Thu, Jan 25, 2024 11:56 CET Report this content
Hamlet BioPharma’s drug candidate Alpha1H has been... |
| 10.01.2024 | Hamlet BioPharma featured at MSQ’s CEO Webinar series released during the JP Morgan Health Care Conference 2024 | Hamlet BioPharma featured at MSQ’s CEO Webinar series released during the JP Morgan Health Care Conference 2024
Wed, Jan 10, 2024 14:53 CET Report this content
Hamlet BioPharma, the innovative pharmaceutical company currently advancing seve... |
| 09.01.2024 | Immunotherapy - a new approach to treating bacterial infections, including antibiotic resistant strains | Immunotherapy - a new approach to treating bacterial infections, including antibiotic resistant strains
Tue, Jan 09, 2024 17:04 CET Report this content
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phas... |
| 29.11.2023 | Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer | Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer
Wed, Nov 29, 2023 09:29 CET Report this content
Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the ... |
| 30.10.2023 | Hamlet BioPharma presented at the FS Market event on October 25th | Hamlet BioPharma presented at the FS Market event on October 25th
Mon, Oct 30, 2023 14:44 CET Report this content
The company was presented by Catharina Svanborg and Jan Zetterberg.
To view the presentation, please use the link bekow:
https... |
| 01.07.2023 | FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer | FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer
Sat, Jul 01, 2023 15:59 CET Report this content
Hamlet Pharma is proud to announce today that the U.S. Food and Drug Administration (FDA) h... |
| 01.07.2023 | FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer | FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer
Sat, Jul 01, 2023 15:59 CET Report this content
Hamlet Pharma is proud to announce today that the U.S. Food and Drug Administration (FDA) h... |
| 30.06.2023 | Petter Segelman Lindqvist appointed new CEO of Hamlet Pharma | Petter Segelman Lindqvist appointed new CEO of Hamlet Pharma
Fri, Jun 30, 2023 09:25 CET Report this content
Hamlet Pharma, soon to be Hamlet BioPharma, the innovative pharmaceutical company with several projects in Phase II trials in infec... |
| 30.06.2023 | Petter Segelman Lindqvist appointed new CEO of Hamlet Pharma | Petter Segelman Lindqvist appointed new CEO of Hamlet Pharma
Fri, Jun 30, 2023 09:25 CET Report this content
Hamlet Pharma, soon to be Hamlet BioPharma, the innovative pharmaceutical company with several projects in Phase II trials in infec... |
| 12.06.2023 | Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group | Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group
Mon, Jun 12, 2023 13:14 CET Report this content
Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharma... |
| 12.06.2023 | Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group | Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group
Mon, Jun 12, 2023 13:14 CET Report this content
Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharma... |
| 09.06.2023 | Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET | Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET
Fri, Jun 09, 2023 10:10 CET Report this content
Lund, June 9, Hamlet Pharma soon to be Hamlet BioPharma, the innova... |
| 09.06.2023 | Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET | Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET
Fri, Jun 09, 2023 10:10 CET Report this content
Lund, June 9, Hamlet Pharma soon to be Hamlet BioPharma, the innova... |
| 31.05.2023 | Hamlet Pharma secures a new Alpha1H production batch for continued clinical trials | Hamlet Pharma secures a new Alpha1H production batch for continued clinical trials
Wed, May 31, 2023 10:20 CET Report this content
Lund, May 31, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong ... |
| 31.05.2023 | Hamlet Pharma secures a new Alpha1H production batch for continued clinical trials | Hamlet Pharma secures a new Alpha1H production batch for continued clinical trials
Wed, May 31, 2023 10:20 CET Report this content
Lund, May 31, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong ... |
| 26.05.2023 | Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023 | Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023
Fri, May 26, 2023 08:00 CET Report this content
Opening remarks
During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alp... |
| 26.05.2023 | Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023 | Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023
Fri, May 26, 2023 08:00 CET Report this content
Opening remarks
During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alp... |
| 22.05.2023 | Introducing Hamlet BioPharma to investors | Introducing Hamlet BioPharma to investors
Mon, May 22, 2023 10:10 CET Report this content
Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches t... |
| 22.05.2023 | Introducing Hamlet BioPharma to investors | Introducing Hamlet BioPharma to investors
Mon, May 22, 2023 10:10 CET Report this content
Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches t... |
| 14.04.2023 | Hamlet Pharma achieves full funding from the European Commission | Hamlet Pharma achieves full funding from the European Commission
Fri, Apr 14, 2023 15:20 CET Report this content
In a recent evaluation of Hamlet Pharma, the European Commission concluded that Hamlet Pharma’s bladder cancer project has deli... |
| 06.04.2023 | Notice of extraordinary general meeting in Hamlet Pharma AB (publ) | Notice of extraordinary general meeting in Hamlet Pharma AB (publ)
Thu, Apr 06, 2023 08:00 CET Report this content
The shareholders of Hamlet Pharma AB (publ) (“Hamlet Pharma” or the “Company”), reg. no. 556568-8958, are hereby invited to t... |
| 31.03.2023 | Hamlet Pharma & SelectImmune Pharma invites to a digital investor meeting on April 3rd and April 4th at 12.00 CET | Hamlet Pharma & SelectImmune Pharma invites to a digital investor meeting on April 3rd and April 4th at 12.00 CET
Fri, Mar 31, 2023 08:06 CET Report this content
Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharma... |
| 17.03.2023 | Hamlet Pharma’s achievements regarded as ‘‘exceptional’’ by the European Commission after final review of the Horizon 2020 project | Hamlet Pharma’s achievements regarded as ‘‘exceptional’’ by the European Commission after final review of the Horizon 2020 project
Fri, Mar 17, 2023 15:57 CET Report this content
Hamlet Pharma, listed on Spotlight Stock Market, was awarded ... |
| 22.11.2022 | Hamlet Pharma holds a digital investor meeting | Hamlet Pharma holds a digital investor meeting
Tue, Nov 22, 2022 09:42 CET Report this content
Hamlet Pharma is inviting you to a digital investors’ meeting via Zoom, on Wednesday 30th November at 12.00 CET, for dialogue and to follow up fr... |
| 11.11.2022 | Hamlet Pharma Q1 Interim Report July 2022 – September 2022 | Hamlet Pharma Q1 Interim Report July 2022 – September 2022
Fri, Nov 11, 2022 08:30 CET Report this content
Opening remarks
The HAMLET family of drug candidates has remarkable effects and continues to show great promise for the prevention an... |
| 09.11.2022 | BAMLET in the drinking water; protection against intestinal cancer and potent beneficial health effects | BAMLET in the drinking water; protection against intestinal cancer and potent beneficial health effects
Wed, Nov 09, 2022 14:44 CET Report this content
Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are... |
| 26.08.2022 | Hamlet Pharma Year-end Report July 2021 – June 2022 | Hamlet Pharma Year-end Report July 2021 – June 2022
Fri, Aug 26, 2022 08:30 CET Report this content
Opening remarks
The fiscal year 2021/2022 of Hamlet Pharma AB has been very successful and important milestones have been reached. The compa... |
| 02.08.2022 | Full speed ahead! – Hamlet Pharma adapts the clinical trial program for stand-alone use | Full speed ahead! – Hamlet Pharma adapts the clinical trial program for stand-alone use
Tue, Aug 02, 2022 10:28 CET Report this content
Hamlet Pharma develops new drug candidates to treat cancer without causing significant side effects. The... |
| 13.06.2022 | Brain tumor therapy – A new indication for Hamlet Pharma | Brain tumor therapy – A new indication for Hamlet Pharma
Mon, Jun 13, 2022 14:41 CET Report this content
Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading ex... |
| 20.05.2022 | Hamlet Pharma Q3 Interim Report January – March 2022 | Hamlet Pharma Q3 Interim Report January – March 2022
Fri, May 20, 2022 08:30 CET Report this content
Hamlet Pharma has reached important milestones during the third quarter of the fiscal year 2021-2022. We have successfully completed the do... |
| 18.05.2022 | Newsletter - Recent Presentations of Hamlet Pharma | Newsletter - Recent Presentations of Hamlet Pharma
Wed, May 18, 2022 12:50 CET Report this content
Hamlet Pharma has participated in a number of recent events, presenting highligts from the promising clinical studies and our future strategy... |
| 05.04.2022 | Martin Erixon joins Hamlet Pharma as new CEO | Martin Erixon joins Hamlet Pharma as new CEO
Tue, Apr 05, 2022 11:23 CET Report this content
Hamlet Pharma enters a new business development phase involving multiple cancer indications and markets. Based on the successful outcomes of our cl... |
| 04.03.2022 | Successful review of HAMLET Pharma by the EU Horizon 2020 program | Successful review of HAMLET Pharma by the EU Horizon 2020 program
Fri, Mar 04, 2022 09:10 CET Report this content
Hamlet Pharma has recently delivered its 18-month report to the European Union’s Horizon 2020 program. In their response, the ... |
| 25.02.2022 | Hamlet Pharma AB Interim Report Q2; October – December 2021 | Hamlet Pharma AB Interim Report Q2; October – December 2021
Fri, Feb 25, 2022 08:30 CET Report this content
Opening remarks
The second quarter of the fiscal year 2021/2022 has been very productive ending on a high with the completion of the... |
| 31.01.2022 | Hamlet NEWSLETTER Important steps forward towards treating bladder cancer | Hamlet NEWSLETTER Important steps forward towards treating bladder cancer
Mon, Jan 31, 2022 09:09 CET Report this content
We are pleased to inform you that our clinical dose escalation study with the Hamlet peptide drug Alpha1H in patients ... |
| 17.01.2022 | Successful completion of the dose escalation study in patients with bladder cancer | Successful completion of the dose escalation study in patients with bladder cancer Mon, Jan 17, 2022 12:15 CET
Hamlet Pharma has previously reported the successful completion of a Phase I/II study using a 1.7 mM dose of Alpha1H. We are now ... |
| 14.01.2022 | NEW STRATEGIC RECRUITS TO HAMLET PHARMA | NEW STRATEGIC RECRUITS TO HAMLET PHARMA Fri, Jan 14, 2022 14:59 CET
To continue Hamlet Pharma’s drug development process towards Phase III trials and future commercialization, it is essential to expand our organization. We are therefore gat... |
| 07.12.2021 | Hamlet Pharma focuses on communication | Hamlet Pharma focuses on communication Tue, Dec 07, 2021 15:25 CET
Hamlet Pharma is increasing its focus on the company’s digital channels, to provide easier access for shareholders and the public. So far, this effort includes an updated we... |
| 30.11.2021 | Hamlet Pharma has signed a collaboration agreement with Galenica | Hamlet Pharma has signed a collaboration agreement with Galenica Tue, Nov 30, 2021 08:50 CET
Hamlet Pharma is proceeding with the development of BAMLET for pharmaceutical use. A necessary first step is to establish technology for large-scal... |
| 11.11.2021 | Komplettering: Hamlet Pharma AB: Hamlet Pharma Interim report Q1; July–September 2021 | Komplettering: Hamlet Pharma AB: Hamlet Pharma Interim report Q1; July–September 2021 Thu, Nov 11, 2021 11:31 CET
Nu med text inlagd i meddelandet.
Opening remarks
During the first quarter of the new fiscal year, Hamlet Pharma secured conti... |
| 11.11.2021 | Hamlet Pharma Interim report Q1; July–September 2021 | Hamlet Pharma Interim report Q1; July–September 2021 Thu, Nov 11, 2021 08:30 CET
The Interim report Q1 for the period July 2021 - September 2021 is attached as pdf. It can also be found on Hamlet Pharma's homepage www.hamletpharma.com.
For ... |
| 29.10.2021 | Hamlet Pharma secures Alpha1H production for continued clinical trials | Hamlet Pharma secures Alpha1H production for continued clinical trials Fri, Oct 29, 2021 12:55 CET
It is a great pleasure to announce that Hamlet Pharma has secured the production of larger quantities of Alpha1H, using a stable, large scale... |
| 10.06.2021 | A NEW APPROACH TO CANCER THERAPY – Results of a placebo-controlled clinical trial published in Nature Communications | A NEW APPROACH TO CANCER THERAPY – Results of a placebo-controlled clinical trial published in Nature Communications Thu, Jun 10, 2021 09:18 CET
The serendipitous discovery of HAMLET has provided novel insights into how to kill tumor cells ... |
| 07.06.2021 | Tetra Pak, Hamlet Pharma and Linnane Pharma have signed a Letter of Intent regarding the development of consumer products | Tetra Pak, Hamlet Pharma and Linnane Pharma have signed a Letter of Intent regarding the development of consumer products Mon, Jun 07, 2021 15:48 CET
Hamlet and Tetra Pak wish to explore the possibilities to include into food products the a... |
| 21.05.2021 | Q3 Interim Report January 2021 – March 2021 | Q3 Interim Report January 2021 – March 2021 Fri, May 21, 2021 08:30 CET
Opening remarks
The third quarter has been an intense and exciting period for Hamlet Pharma.
In January, the first patients were included in the dose-escalation part of... |
